Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Dapagliflozin in T2DM and NAFLD
NCT05459701Phase 4Completed
- Sponsor
- Rehab Werida
- Start
- May 2022
- Primary completion
- Jun 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 4 trial of dapagliflozin in non-alcoholic fatty liver disease (NAFLD), sponsored by Rehab Werida. Started May 2022; status: completed.
02
Drugs
dapagliflozin
03
Conditions
non-alcoholic fatty liver disease (NAFLD)
Beyond the preview
Go deeper on NCT05459701.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05459701.